Browse All

Current Filters

CLEAR FILTER x

TITLE

Program Number:

Annualized Rates of Change from A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 48-Week Study of Losmapimod in Subjects with FSHD: ReDUX4

Author:Tawil, Alrabi   

Session Name:S48: Therapeutics for Muscle Disease  

Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

Program Number:S48.010  

Author Institution:University of Rochester Medical Center, Rochester, NY